Evidence map›Paper›PMID 42294175›Full record

ArticleACS omega2026

Learning to See Peaks: Attention-Based Feature Extraction for Automated Chromatographic Peak Detection.

Daniel Walter, Mathias Helbig, Birgit Weydanz, Dominik Voltmer, Juan Jose Bonfiglio, Carsten Marr, Tobias Großkopf

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniel WalterPharma Research and Early Development, Roche Diagnostics GmbH, Penzberg 82377 Germany.ORCID https://orcid.org/0009-0008-9587-3731
Mathias HelbigPharma Research and Early Development, Roche Diagnostics GmbH, Penzberg 82377 Germany.
Birgit WeydanzPharma Research and Early Development, Roche Diagnostics GmbH, Penzberg 82377 Germany.
Dominik VoltmerPharma Research and Early Development, Roche Diagnostics GmbH, Penzberg 82377 Germany.ORCID https://orcid.org/0000-0001-5929-1680
Juan Jose BonfiglioPharma Research and Early Development, Roche Diagnostics GmbH, Penzberg 82377 Germany.ORCID https://orcid.org/0000-0001-7767-0799
Carsten MarrDepartment of Medicine III, Ludwig-Maximilian-University Hospital, Marchioninistr. 15, Munich 81377, Germany.
Tobias GroßkopfPharma Research and Early Development, Roche Diagnostics GmbH, Penzberg 82377 Germany.ORCID https://orcid.org/0000-0002-5160-5152

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reliable peak detection remains a bottleneck in size-exclusion chromatography (SEC) as overlapping signals, drifting baselines, and analyst variability limit reproducibility. As SEC is a routine release and comparability assay and its interpretation depends on peak morphology and context, machine learning methods are well-suited to improve reproducibility at scale. We present the Peak Feature Extractor 1 (PFE-1), a one-dimensional encoder-only transformer trained on millions of synthetic chromatograms generated by a simulator statistically calibrated to routine SEC data from antibodies and related large-molecule species. PFE-1 outputs probabilistic region and event predictions that are aggregated through a transparent rule-based procedure into interpretable peak boxes. We evaluate PFE-1 on synthetic benchmarks and on a curated real SEC benchmark, reporting window-level precision/recall/F1 and box-level agreement via an intensity-weighted box loss aligned with routine process annotations. Across these evaluations, PFE-1 outperforms convolutional and derivative-based baselines, with the largest gains observed under more challenging overlap and morphology conditions. On synthetic data, PFE-1 achieves substantially higher box-level agreement than both baselines; on the curated real SEC benchmark, it likewise achieves the strongest box-level agreement while requiring no sample-specific inputs (e.g., expected peak windows). We provide a reproducible and extensible SEC-specific framework for chromatographic peak detection that supports a more consistent peak interpretation in routine analytical workflows.

Identifiers

PMID42294175
PMCPMC13261407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.